A Pilot Study of Technetium [99Tc] Methylene Diphosphonate in the Treatment of Psoriatic Arthritis

Phase 4

Completed

• Conditions: Arthritis, Psoriatic
• Interventions: Drug: 99Tc methylene diphosphonate

• Registration Number: NCT05000086
• Lead Sponsor: Peking Union Medical College Hospital

Brief Summary

This study is aim to evaluate the efficacy and safety of technetium \[99Tc\] methylene diphosphonate (99Tc-MDP, trade name: Yunke) in the treatment of psoriatic arthritis.

Detailed Description

This is a single-arm, open label, 24 weeks study. Patients with psoriatic arthritis get 99Tc-MDP 22mg (5.5mg/set, four sets) was injected intravenously once a day for 7 successive days, one course every 4 weeks until week 24.

Study Timeline

• Study Start: 2019-06-01
• Status Verified: 2021-07
• Primary Completion: 2021-07-01
• Study Completion: 2021-07-01
• Study First Submitted: 2021-08-03
• Study First Submitted QC: 2021-08-03
• Last Update Submitted: 2021-08-03
• Study First Posted: 2021-08-11
• Last Update Posted: 2021-08-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• 18-70 years of age;

• Clinical diagnosis of PsA according to the CASPAR classification criteria

• Active PsA at baseline defined as ≥ 3 tender joints and ≥ 3 swollen joints

• If subjects were taking csDMARDs, the doses of csDMARDs had to be stable for at least 4 weeks and had to remain the same during the trial

• The application of bDMARDs and tsDMARDs should meet the following requirements:

  1. Etanercept and its biological analogues: stop at least 4 weeks prior to their baseline visit;
  2. Other biological: stop at least 6 months prior to their baseline visit
  3. tsDMARDs: stop at least 8 weeks prior to their baseline visit

• If subjects were taking glucocorticoids, the doses of GC(prednisone < 10mg) had to be stable for at least 4 weeks and had to remain the same during the trial;

• Non steroidal anti-inflammatory drugs: if applied, the dose was stable one week prior to their baseline visit

• Negative pregnancy test for child-bearing women at screening and baseline

• Provide written informed consent

Exclusion Criteria

• Patients with severe heart, liver, kidney and other important organ diseases
• Abnormal liver function (ALT or AST is 2 times higher than normal)
• White blood cell count less than 4,000/mm^3 (less than 4 X 10^9/L)
• Platelet count less than 100,000/mm^3 (less than 100 X 10^9/L)
• Serum creatinine more than or equal to 1.5 mg/dL (less than or equal to 132.6 μmol/L)
• Pregnancy or breastfeeding women
• Contraindications to 99Tc-MDP therapy and/or known hypersensitivity to 99Tc-MDP
• Participated in other drugs clinical trials within 4 weeks

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
99Tc methylene diphosphonate	99Tc methylene diphosphonate	99Tc-MDP was applied as follows: for each course of treatment, 99Tc-MDP 22 mg (5.5mg/set, four sets) was injected intravenously once a day for 7 successive days, one course every 4 weeks until week 24.

Primary Outcome Measures

Name	Time	Method
Proportion of Patients Achieving DAS28-CRP<=3.2	24 weeks	DAS28-CRP: Disease Activity Score based on a count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (CRP) and the patient's own assessment. Scores can take any positive value with a lower value indicating a better clinical condition. DAS28-CRP score of \<=3.2 indicates low disease activity. \<2.6 means disease remission
Proportion of Patients Achieving DAS28-ESR<=3.2	24 weeks	DAS28-ESR: Disease Activity Score based on a count of swollen and tender joints (out of 28 joints), blood test measures of inflammation (ESR) and the patient's own assessment. Scores can take any positive value with a lower value indicating a better clinical condition. DAS28-ESR score of \<=3.2 indicates low disease activity. \<2.6 means disease remission

Secondary Outcome Measures

Name	Time	Method
Change in PASI From Baseline From Baseline	24 weeks	Psoriasis Area and Severity Index
Change in HAQ-DI Score From Baseline	24 weeks	The HAQ-DI is a standardized measure of physical function in arthritis. The HAQ-DI questionnaire contains 20 items divided into 8 domains that measure: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability.
ACR20	12 weeks	The ACR is a standard criteria originally developed to measure the effectiveness of various arthritis medications or treatments in clinical trials for RA, but is also widely used in PsA. The ACR measures improvement in tender joint count (TJC) or swollen joint count (SJC), and improvement in at least 3 of the following 5 parameters: Patient Global Assessment (PtGA), Physician's Global Assessment of Disease Activity (PhGA), physical function (using HAQ-DI) and acute phase reactant (using CRP). ACR 20 response is achieved if ≥ 20% improvement in tender joint count (TJC) or swollen joint count (SJC) as well as a ≥ 20%/≥ 50%/≥ 70% improvement in ≥ 3 of the other 5 parameters.
Change in Disease Activity in Psoriatic Arthritis Score (DAPSA) Score From Baseline	24 weeks	Disease Activity in Psoriatic Arthritis Score (DAPSA) score is a the sum of swollen joint count (66 joints), tender joint count (68 joints), CRP (mg/dL), Patient's Assessment of Pain (on a 10-unit VAS;0=no pain, 10=worst possible pain), and Patient's Global Assessment of Disease Activity (arthritis, on a 10-unit VAS; 0 to 100 centimeter \[cm\] VAS, 0=excellent and 10=poor). Change from baseline in DAPSA measures the change in disease activity, where a negative change indicates an improvement and a positive change indicates worsening of disease activity.
Percentage of Participants in MDA	24 weeks	MDA for PsA was defined as fulfilling at least 5 of the following 7 criteria: TJC ≤ 1 (out of TJC68 assessed in this study), SJC ≤ 1 (out of SJC66 assessed in this study), PASI ≤ 1 or BSA ≤ 3; Patient's assessment of pain VAS ≤ 15, PtGA VAS ≤ 20, HAQ-DI score ≤ 0.5, and tender entheseal points ≤ 1
Change in Tender Joint Count (TJC) 68 from baseline	12 weeks and 24 weeks	TJC is determined by physical examination of 68 joint counts that are assessed for tenderness.
Change in Swollen Joint Count (SJC) 66 from baseline	12 weeks and 24 weeks	SJC is determined by physical examination of 66 joint counts that are classified as either swollen or not swollen.

Trial Locations

Locations (1)

Peking Union Medical College hospital; 🇨🇳 Beijing, Dongcheng, China